Related Experiment Videos
Moderate hyperhomocysteinaemia and vascular disease: evidence, relevance and the effect of treatment
1Department of General Internal Medicine, University Hospital Nijmegen, The Netherlands.
Insights
Moderate hyperhomocysteinemia is a significant risk factor for vascular disease, comparable to high cholesterol and smoking. Lowering homocysteine levels through vitamin intervention shows promise, but clinical outcome data are still needed.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Vascular Biology
Background:
- Moderate hyperhomocysteinemia is an emerging risk factor for vascular disease.
- Its risk is independent of conventional factors like hypercholesterolemia and smoking.
- Evidence suggests a synergistic effect with hypertension and smoking.
Purpose of the Study:
- To highlight the significance of hyperhomocysteinemia as a vascular disease risk factor.
- To emphasize the potential of homocysteine-lowering interventions.
- To underscore the need for clinical trials on treatment outcomes.
Main Methods:
- Review of accumulated evidence on hyperhomocysteinemia and vascular disease.
- Analysis of synergistic interactions with other risk factors.
- Assessment of vitamin regimens for homocysteine reduction.
Main Results:
- Hyperhomocysteinemia is a strong, independent risk factor for vascular disease.
- Synergistic effects with hypertension and smoking enhance arteriosclerosis.
- Vitamin interventions effectively lower homocysteine levels.
Conclusions:
- Homocysteine-lowering interventions are promising, especially for patients with multiple risk factors.
- Safe and inexpensive vitamin regimens can reduce homocysteine.
- Clinical trials are urgently required to confirm the benefits of homocysteine reduction on patient outcomes.
Unlabelled:
Convincing evidence of moderate hyperhomocysteinaemia as a risk factor for vascular disease has accumulated within the last decade being independent of conventional risk factors and equally strong as hypercholesterolaemia and smoking. A synergistic interaction with hypertension and smoking in their joint arteriosclerotic effect in patients is demonstrated which makes the result of homocysteine-lowering intervention very promising, especially in those vascular patients with an association of these risk factors.
Conclusion:
Despite the proven homocysteine-lowering effect of intervention with sample, safe, and cheap vitamin regimen, no data are so far available on the clinical outcome of such treatment. Clinical trials to demonstrate a hopefully beneficial result of homocysteine reduction are urgently needed.